Lupin is currently trading at Rs. 814.00, up by 6.05 points or 0.75% from its previous closing of Rs. 807.95 on the BSE.
The scrip opened at Rs. 808.00 and has touched a high and low of Rs. 818.70 and Rs. 800.90 respectively. So far 140181 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1520.00 on 09-Feb-2017 and a 52 week low of Rs. 782.10 on 07-Feb-2018.
Last one week high and low of the scrip stood at Rs. 883.00 and Rs. 782.10 respectively. The current market cap of the company is Rs. 36795.22 crore.
The promoters holding in the company stood at 47.02%, while Institutions and Non-Institutions held 37.64% and 15.35% respectively.
Lupin has launched Clonidine Hydrochloride extended-release tablets, 0.1 mg, having received an approval from the United States Food and Drug Administration (USFDA) earlier. Kapvay tablets had annual sales of around $66 million in the US (IQVIA MAT December 2017).
Lupin's Clonidine Hydrochloride ER tablets is the generic equivalent of Concordia International Corp's Kapvay tablets. It is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy or as adjunctive therapy to stimulant medications.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
